Literature DB >> 2940268

Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study.

R M Halder, C S Walters, B A Johnson, S G Chakrabarti, J A Kenney.   

Abstract

Twenty-five patients with vitiligo and twenty-five healthy control subjects were evaluated with the use of flow cytometry to compare percentages of peripheral T lymphocytes and natural killer cells. The percentages of total T lymphocytes, helper T cells, suppressor T cells, and natural killer cells were evaluated with the use of OKT3, OKT4, OKT8, and Leu-7 monoclonal antibodies, respectively. Mean total T lymphocytes and helper T cells were markedly depressed; mean natural killer cells were markedly elevated and mean suppressor T cells were moderately elevated in patients with vitiligo in comparison with control subjects. These results indicate that cell-mediated immunity is subject to some defect in regulation in patients with vitiligo. It remains to be determined whether these abnormalities are a direct cause or a result of vitiligo. Antibody-dependent cytotoxicity, utilizing killer cells with recently reported antimelanocyte antibodies found in patients, may be responsible for pigment cell destruction in vitiligo. Helper T cells may be reduced because of low levels or faulty production of T lymphocyte-stimulating factors in patients or because of a serum factor in patients that is toxic to helper T cells. The presence or absence of autoimmune and/or endocrine disease in patients with vitiligo had no effect on lymphocyte populations. There seemed to be a trend toward lower levels of helper T cells in patients having vitiligo for the shortest amount of time. In summary, the data indicate immunologic abnormalities in patients with vitiligo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940268     DOI: 10.1016/s0190-9622(86)70085-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

1.  Epidermal permeability barrier recovery is delayed in vitiligo-involved sites.

Authors:  J Liu; W Y Man; C Z Lv; S P Song; Y J Shi; P M Elias; M Q Man
Journal:  Skin Pharmacol Physiol       Date:  2010-02-25       Impact factor: 3.479

2.  Participation of T cell immunoglobulin and mucin domain-3 (TIM-3) and its ligand (galectin-9) in the pathogenesis of active generalized vitiligo.

Authors:  Manoj Kumar Tembhre; Anita Singh Parihar; Alpana Sharma; Somesh Gupta; Parthaprasad Chattopadhyay; Vinod Kumar Sharma
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

3.  Evaluation of Histologically and Histochemically Proven Cases of Vitiligo and its Correlation with CD4+ and CD8+ Lymphocyte Counts using Flow Cytometry.

Authors:  Moninder Kaur; Permeet Kaur Bagga; Tejinder Kaur; Amarjit Singh Kataria
Journal:  J Clin Diagn Res       Date:  2017-05-01

4.  Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio.

Authors:  Robert Pichler; Konstantin Sfetsos; Birgit Badics; Sabrina Gutenbrunner; Jörg Berg; Josef Auböck
Journal:  Wien Med Wochenschr       Date:  2009

5.  Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome.

Authors:  M El-Domyati; W H El-Din; A F Rezk; I Chervoneva; J B Lee; M Farber; J Uitto; O Igoucheva; Vitali Alexeev
Journal:  Arch Dermatol Res       Date:  2021-04-17       Impact factor: 3.017

6.  A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat.

Authors:  Shahnawaz D Jadeja; Mohmmad Shoab Mansuri; Mala Singh; Mitesh Dwivedi; Naresh C Laddha; Rasheedunnisa Begum
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

7.  Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo.

Authors:  Meri K Tulic; Elisa Cavazza; Yann Cheli; Arnaud Jacquel; Carmelo Luci; Nathalie Cardot-Leccia; Hanene Hadhiri-Bzioueche; Patricia Abbe; Maéva Gesson; Laura Sormani; Claire Regazzetti; Guillaume E Beranger; Cedric Lereverend; Caroline Pons; Abdallah Khemis; Robert Ballotti; Corine Bertolotto; Stéphane Rocchi; Thierry Passeron
Journal:  Nat Commun       Date:  2019-05-16       Impact factor: 14.919

Review 8.  Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective.

Authors:  Katia Boniface; Thierry Passeron; Julien Seneschal; Meri K Tulic
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

9.  Increased Circulatory Interleukin-17A Levels in Patients with Progressive and Leukotrichial Vitiligo.

Authors:  Thai Van Thanh Le; Huy Ngoc Phan; Tran Ngoc Dang; Le Duy Pham
Journal:  Dermatol Res Pract       Date:  2021-04-21

Review 10.  Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.

Authors:  Yinghan Wang; Shuli Li; Chunying Li
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-20       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.